Symonds W, Cutrell A, Edwards M, et al.Risk factor analysis of hypersensitivity reactions to abacavir. Clin Ther2002; 24(4): 565-573.
2.
Hetherington S, Hughes A, Mosteller, et al.HLA-B57 and TNF-alpha variants associated with hypersensitivity reactions to abacavir among HIV-1-positive subjects. 9th Conference on Retroviruses and Opportunistic Infections. February 24-28, 2002. Seattle, WA. (Abstract 92).
3.
Hetherington S, Steel H, Naderer O, et al.Hypersensitivity reactions during therapy with abacavir: analysis of 636 cases for clinical presentation and risk factors. 7th Conference on Retroviruses and Opportunistic Infections. January 30-February 2, 2000. San Francisco, CA. (Abstract 60).
4.
Stern J, Love J, Robinson P, Lanes S, Imperiale M, Mayers D. Hepatic safety of nevirapine: results of the Boehringer Ingelheim Viramunereg. Hepatic Safety Project. 14th International AIDS Conference. July 7-12, 2002. Barcelona, Spain. (Abstract LbOr15).
5.
Pollard RB, Robinson P, Dransfield K. Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection. Clin Ther1998; 20(6):1071-1092.
6.
Berger TG, Obuch ML, Goldschmidt RH. Dermatologic manifestations of HIV infection. Am Fam Physician1990; 41(6):1729-1742.
7.
Lipman M, Gluck T, Johnson M, editors. Atlas of Differential Diagnosis in HIV Disease. New York: Parthenon Publishing Group;1995. Pages 35-50.
8.
Kaplan AP. Clinical Practice. Chronic urticaria and angioedema. N Eng J Med2002; 346(3):175-179.
9.
The diagnosis and management of urticaria: a practice parameter part I: acute urticaria/angioedema part II: chronic urticaria/angioedema. Joint Task Force on Practice Parameters. Ann Allergy Asthma Immunol2000; 85(6 Pt 2):521-544.
